Navigation Links
Jennerex Clinical Trial Data with JX-594 Selected for Plenary Session Presentation at Major International Conference
Date:6/2/2008

SAN FRANCISCO, June 2 /PRNewswire/ -- Jennerex, Inc. (San Francisco, CA and Ottawa, Canada), announced today that David H. Kirn, M.D., President & CEO delivered a plenary session presentation on Friday, May 30, 2008 entitled "Clinical Proof-of-Concept with JX-594, a Novel Targeted Multi-Mechanistic Oncolytic Poxvirus, in Patients with Refractory Liver Tumors" at the American Society of Gene Therapy (ASGT) Annual Meeting in Boston, Massachusetts. This abstract was selected for presentation in the plenary session from over 1,000 abstracts submitted to the conference. The ASGT Meeting is the premier annual international conference covering advancements in viral and genetic therapies for cancer.

In addition, Dr. John C. Bell, Chief Scientific Officer, delivered a presentation at the same conference, on Thursday, May 29, 2008, entitled "Oncolytic Virus Therapies of Cancer." In a third presentation by Jennerex R and D leaders, Dr. Kirn delivered a presentation on Jennerex product development entitled "Design and Development of Targeted and Armed Oncolytic Poxviruses, a Novel Therapeutic Class."

This follows on Jennerex's recent announcement that Phase I clinical trial results from its first-in-class lead product JX-594 were published in the premier journal Lancet Oncology. The majority of these end-stage patients with solid tumors had objective tumor destruction and responses following treatment with the cancer biotherapeutic. Half of the JX-594-treated patients survived for more than eight months, well beyond their life expectancies of three to four months, and four patients with tumor responses survived for 11 to over 18 months. Results were especially promising for liver and lung cancer patients. Importantly, treatment with JX-594 was shown to be well-tolerated. A Phase II clinical trial is now underway for JX-594 in liver cancer. The world-wide liver cancer market is estimated at over one billion dollars per year.

About JX-594

JX-594 is a cancer biotherapeutic, currently in Phase II trials, from a proprietary class of targeted and armed oncolytic poxviruses. Tumor destruction and safety was shown in patients with diverse cancer types in three Phase I trials; treated patients were end-stage and had no effective therapies available. JX-594 multiplies selectively within cancer cells, leading to their destruction. These newly created copies of JX-594 are then released and are able to infect and eradicate other tumor cells both locally and in distant sites in the body. This cycle of JX-594 replication, cancer cell destruction, release and spread is then repeated. Normal cells are not affected by JX-594 resulting in safety and tolerability. The poxvirus strain backbone of JX-594 has been used safely in millions of people as part of a worldwide vaccination program against smallpox. This strain naturally targets cancer cells due to common genetic defects in cancer cells. JX-594 was engineered to enhance this natural safety and cancer-selectivity by deleting its thymidine kinase (TK) gene, thus making it dependent on the cellular TK expressed at persistently high levels in cancer cells. To enhance product efficacy, JX-594 is also engineered to express the GM-CSF protein. GM-CSF complements the cancer cell lysis work of the product candidate, leading to a cascade of events resulting in tumor necrosis, tumor vasculature shutdown and an anti-tumoral immune attack.

About Jennerex

Jennerex is a clinical-stage biopharmaceutical company focused on the development and commercialization of first-in-class, breakthrough targeted oncolytic products for cancer. The company's lead product JX-594, currently in an international Phase II trial for primary liver cancer, demonstrated promising Phase I efficacy and safety results in patients with a diverse array of common large market cancers. Jennerex's products target, attack and eradicate cancers through a novel and potent oncolytic mechanism that is dependent on highly-specific replication of the company's poxviruses in cancer cells. These products simultaneously stimulate the body's immune response to the cancer. Of note, this mechanism of action and the results in patients to date put the company's product class in a leadership position. Jennerex's position is in marked contrast to gene therapy and standard cancer vaccine approaches. For more information about Jennerex and the company's robust pipeline and three clinical-stage products, please visit http://www.jennerex.com.

For more information about this conference, please visit http://www.asgt.org/am08.


'/>"/>
SOURCE Jennerex, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Radiologists encouraged to look beyond cancer for clinically unseen diseases
2. Clinical depression linked to abnormal emotional brain circuits
3. Preclinical study suggests organ-transplant drug may aid in lupus fight
4. Provectus Pharmaceuticals, Inc. Begins Phase 2 Clinical Trial for Metastatic Melanoma
5. Good Clinical Practice Journal Awards: Winners Announced
6. Microsoft Helps Developers of Clinical User Interfaces Improve Efficiency, Patient Safety With Free Toolkit
7. Study Questions Dead-End Cancer Clinical Trials
8. Genomic Health Announces Multiple Studies on Oncotype DX(TM) Presented at 2007 American Society of Clinical Oncology (ASCO) Breast Cancer Symposium
9. Clinical trials present better alternatives for dialysis patients
10. Mirixa Debuts New Clinical Technology Solutions for Enhancing Patient Care
11. IMPACT initiative looks to improve patient participation in clinical trials
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... Battle Creek, Michigan (PRWEB) , ... June 26, 2016 , ... ... abuse, joined as sponsor of the 2016 Cereal Festival and World’s Longest Breakfast Table ... held in honor of the city’s history as home to some of the world’s ...
(Date:6/26/2016)... Carolina (PRWEB) , ... June 26, 2016 , ... ... of a new product that was developed to enhance the health of felines. The ... centuries. , The two main herbs in the PawPaws Cat Kidney Support ...
(Date:6/26/2016)... ... June 26, 2016 , ... ... they have been diagnosed with endometriosis. These women need a treatment plan to ... a comprehensive approach that can help for preservation of fertility and ultimately achieving ...
(Date:6/25/2016)... , ... June 25, 2016 , ... Austin residents seeking ... American College of Mohs Surgery and to Dr. Russell Peckham for medical and surgical ... effective treatment for skin cancer. The selective fellowship in Mohs Micrographic Surgery completed by ...
(Date:6/25/2016)... Viejo, California (PRWEB) , ... June 25, 2016 , ... ... to fit their specific project," said Christina Austin - CEO of Pixel Film Studios. ... fully customizable and all within Final Cut Pro X . Simply select a ...
Breaking Medicine News(10 mins):
(Date:6/26/2016)... OTTAWA, Ontario , June 27, 2016  VMS ... the Company,s Board will take whatever measures required to ... the Company,s stock which is currently listed on the ... S Wexler, Company Chairman and CEO, "We are seeing ... be difficult to understand, not only by the Company, ...
(Date:6/24/2016)... , June 24, 2016  Global Blood ... biopharmaceutical company developing novel therapeutics for the treatment ... today announced the closing of its previously announced ... stock, at the public offering price of $18.75 ... offering were offered by GBT. GBT estimates net ...
(Date:6/24/2016)... The Academy of Managed Care Pharmacy (AMCP) ... would allow biopharmaceutical companies to more easily share health ... and coverage decisions, a move that addresses the growing ... The recommendations address restrictions in the sharing of ... label, a prohibition that hinders decision makers from accessing ...
Breaking Medicine Technology: